Every 10-Q that BioVie, Inc. (BIVI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BIVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIVI filings page.
BioVie Inc. is a clinical-stage biotech reporting a net loss of about $6.1M for the quarter and $11.2M for the six months ended December 31, 2025, both slightly improved versus the prior year as research and administrative costs declined.
The company ended the period with cash and cash equivalents of $20.5M, working capital of roughly $18.8M, and stockholders’ equity of about $19.3M, but its accumulated deficit reached approximately $363.3M. Management states there is substantial doubt about its ability to continue as a going concern without additional financing.
BioVie is advancing bezisterim (NE3107) for Parkinson’s disease, long COVID and Alzheimer’s disease, and BIV201 for cirrhosis and ascites. A Phase 2b Parkinson’s study completed enrollment of 60 patients with topline data expected in the first half of 2026, and a DOD-funded long COVID Phase 2 trial is underway. The Alzheimer’s Phase 3 trial was left underpowered after excluding patients from sites with protocol and cGCP issues. The company also formed Option Therapeutics for a potential spin-off of its liver program and filed an S-1 for a possible IPO.
BioVie Inc. filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $5.1 million, driven by operating expenses of $5.3 million (R&D $2.9 million; G&A $2.3 million). Other income, net, was $0.2 million mainly from interest income.
Cash and cash equivalents rose to $25.0 million from $17.5 million at June 30, 2025, supported by net proceeds of approximately $10.5 million from an August 2025 underwritten offering of units and pre-funded units, each including warrants exercisable at $2.50. Net cash used in operations was $3.0 million.
The company advanced its clinical programs: a Phase 2b study in Parkinson’s disease commenced in April 2025, and the DOD-funded Long COVID Phase 2 study continued, with $336,000 in grant reimbursements recognized this quarter. BioVie disclosed “substantial doubt” about its ability to continue as a going concern, noting dependence on additional financing. A 1-for-10 reverse stock split became effective July 7, 2025. Shares outstanding were 7,540,316 as of November 7, 2025.